Lode J Swinnen
Overview
Explore the profile of Lode J Swinnen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
2669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sterling C, Tsai H, Holdhoff M, Bolanos-Meade J, Luznik L, Fuchs E, et al.
Transplant Cell Ther
. 2021 Jul;
27(10):863.e1-863.e5.
PMID: 34293518
Secondary central nervous system (CNS) lymphoma is a rare and often fatal complication of non-Hodgkin lymphoma (NHL). Treatment options include radiation therapy, high-dose systemic chemotherapy, intrathecal chemotherapy, and high-dose chemotherapy...
12.
Wahl R, Frey E, Jacene H, Kahl B, Piantadosi S, Bianco J, et al.
Cancers (Basel)
. 2021 Jul;
13(11).
PMID: 34204102
Purpose: We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based radiation dose escalation radioimmunotherapy in patients with recurrent non-Hodgkin's lymphoma using the theranostic pair of In and Y anti-CD20 ibritumomab...
13.
Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma
Holdhoff M, Mrugala M, Grommes C, Kaley T, Swinnen L, Perez-Heydrich C, et al.
J Natl Compr Canc Netw
. 2020 Nov;
18(11):1571-1578.
PMID: 33152700
Primary central nervous system lymphomas (PCNSLs) are rare cancers of the central nervous system (CNS) and are predominantly diffuse large B-cell lymphomas of the activated B-cell (ABC) subtype. They typically...
14.
Nabors L, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, et al.
J Natl Compr Canc Netw
. 2020 Nov;
18(11):1537-1570.
PMID: 33152694
The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of adult CNS cancers ranging from noninvasive and surgically curable pilocytic astrocytomas to metastatic brain disease. The involvement...
15.
Imus P, Tsai H, DeZern A, Jerde K, Swinnen L, Bolanos-Meade J, et al.
Biol Blood Marrow Transplant
. 2020 Sep;
26(12):2306-2310.
PMID: 32961372
Transplant-associated thrombotic microangiopathy (taTMA) is a systemic vascular illness associated with significant morbidity and mortality, resulting from a convergence of risk factors after allogeneic blood or marrow transplantation (alloBMT). The...
16.
DeZern A, Elmariah H, Zahurak M, Rosner G, Gladstone D, Ali S, et al.
Biol Blood Marrow Transplant
. 2020 Aug;
26(11):2075-2081.
PMID: 32818556
With post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis, nonmyeloablative (NMA) HLA-haploidentical (haplo) and HLA-matched blood or marrow transplantation (BMT) have comparable outcomes. Previous reports have shown that discontinuation of...
17.
Persky D, Li H, Stephens D, Park S, Bartlett N, Swinnen L, et al.
J Clin Oncol
. 2020 Jul;
38(26):3003-3011.
PMID: 32658627
Purpose: Diffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in 25% to 30% of patients, with better overall survival (OS) than that for advanced-stage disease but with continuous...
18.
Paul S, Zahurak M, Luznik L, Ambinder R, Fuchs E, Bolanos-Meade J, et al.
Biol Blood Marrow Transplant
. 2020 Jun;
26(9):1679-1688.
PMID: 32592857
: Immune checkpoint inhibitors (ICIs) are approved in relapsed classic Hodgkin lymphoma (cHL). The safety and effectiveness of allogeneic blood or marrow transplantation (alloBMT) in ICI-pretreated patients with cHL remain...
19.
DeZern A, Zahurak M, Symons H, Cooke K, Rosner G, Gladstone D, et al.
Blood Adv
. 2020 Apr;
4(8):1770-1779.
PMID: 32343796
Severe aplastic anemia (SAA) is a stem cell disorder often treated with bone marrow transplantation (BMT) to reconstitute hematopoiesis. Outcomes of related HLA-haploidentical (haplo) donors after reduced-intensity conditioning with intensive...
20.
Paul S, Tsai H, Lowery P, Fuchs E, Luznik L, Bolanos-Meade J, et al.
Biol Blood Marrow Transplant
. 2019 Nov;
26(3):502-508.
PMID: 31730920
Allogeneic blood or marrow transplantation (allo-BMT) remains the only treatment for chronic lymphocytic leukemia (CLL) with curative potential. Although post-transplantation cyclophosphamide (PTCy) reduces allo-BMT toxicity by decreasing the risk of...